

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

BO AHRÉN, MD, PHD¹
 JAMES E. FOLEY, PHD²
 ELE FERRANNINI, MD³
 DAVID R. MATTHEWS, MD⁴

BERNARD ZINMAN, MD⁵
 SYLVIE DEJAGER, MD, PHD⁶
 VIVIAN A. FONSECA, MD, FRCP⁷

OBJECTIVE — To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal.

RESEARCH DESIGN AND METHODS — Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in a trial evaluating add-on therapy to metformin with 50 mg vildagliptin b.i.d. compared with glimepiride up to 6 mg q.d. in type 2 diabetes (baseline A1C $7.3 \pm 0.6\%$).

RESULTS — A1C and prandial glucose area under the curve (AUC)_{0–2 h} were reduced similarly in both groups, whereas prandial insulin AUC_{0–2 h} increased to a greater extent by glimepiride. Prandial glucagon AUC_{0–2 h} (baseline $66.6 \pm 2.3 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$) decreased by $3.4 \pm 1.6 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ by vildagliptin ($n = 137$) and increased by $3.8 \pm 1.7 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ by glimepiride ($n = 121$). The between-group difference was $7.3 \pm 2.1 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ ($P < 0.001$).

CONCLUSIONS — Vildagliptin therapy but not glimepiride improves postprandial α -cell function, which persists for at least 2 years.

Diabetes Care 33:730–732, 2010

Glucagon levels are increased in type 2 diabetes because of impaired glucose-mediated suppression of glucagon secretion resulting in increased hepatic glucose output with subsequent hyperglycemia (1). Improved glycemia by the dipeptidyl peptidase-4 inhibitor, vildagliptin (2), is mediated primarily by improved β - and α -cell sensitivity to glucose (3). As an add-on to metformin, vildagliptin displays equal efficacy as

glimepiride, with the added benefits of a much lower risk of hypoglycemia and no weight gain (4). Here we report prandial assessments of glucagon levels and insulin secretion rates after up to ~2 years of therapy with the two drugs.

RESEARCH DESIGN AND METHODS

The study was an extension to 2 years of a previously described study (4). Standard meal

challenge was performed in selected centers at last treatment visit after administration of a morning dose of metformin plus 50 mg vildagliptin or up to 6 mg glimepiride (mean treatment period 1.8 years). Doses were selected to achieve comparable improvements in glycemia. After an overnight fast, a mixed meal was served (orange juice [180 ml], two slices [60 g] of white bread, 30 g jam, 15 g butter or margarine, 120 ml whole milk [3–4% fat] or equivalent amount of cheese plus 120 ml water, and, if desired, decaffeinated coffee or tea; 510 kcal, with 50% from carbohydrate, 38% from fat, and 12% from protein). Blood samples were taken before the meal and at 15, 30, 60, 90, 120, 180, and 240 min.

Analytical determinations

Plasma glucose concentration was determined by the glucose oxidase method (Beckman Glucose Analyzer II; Beckman Instruments, Fullerton, CA). Plasma insulin, C-peptide, and glucagon concentrations were determined by radioimmunoassay (Diagnostics Products, Los Angeles, CA). Plasma intact glucagon-like peptide (GLP)-1 concentration was measured by ELISA using an NH₂-terminal-specific antibody (Linco Research, St. Charles, MO) by Novartis.

Calculations

Insulin secretory rate was determined as described previously (5). The absolute and incremental/decremental areas under the curve (AUCs) for time 0–2 h after the meal were calculated using the trapezoidal method. End point changes from baseline were assessed using ANCOVA.

Ethics

The study was conducted in accordance with the Declaration of Helsinki. It was reviewed by an independent ethics committee or institutional review board for each center. Written informed consent was obtained from each subject.

From the ¹Department of Medicine, Lund University, Lund, Sweden; ²Novartis Pharmaceuticals, East Hanover, New Jersey; the ³Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa, Pisa, Italy; the ⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital and National Institute of Health Research, Oxford Biomedical Research Centre, Oxford, U.K.; the ⁵Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; ⁶Clinical Research, Novartis Pharma SAS, Rueil-Malmaison, France; and the ⁷Department of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana.

Corresponding author: Bo Ahrén, bo.ahren@med.lu.se.

Received 8 October 2009 and accepted 27 December 2009. Published ahead of print at <http://care.diabetesjournals.org> on 12 January 2010. DOI: 10.2337/dc09-1867. Clinical trial reg. no. NCT00106340, clinicaltrials.gov.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

RESULTS— Baseline characteristics were as follows: patient demographics of the subpopulation who participated in the meal challenge ($n = 259$) were essentially the same as reported previously (4). Mean baseline A1C was $7.3 \pm 0.6\%$.

A1C, glucose, and insulin

At the follow-up meal test (up to 2 years after start; mean 1.8 years), A1C was reduced by $-0.1 \pm 0.9\%$ in the vildagliptin group ($n = 137$) versus $-0.2 \pm 0.8\%$ in the glimepiride group ($n = 121$). Prandial glucose $AUC_{0-2\text{ h}}$ was similarly reduced in both groups ($-1.7 \text{ mmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for vildagliptin vs. $-2.1 \text{ mmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for glimepiride), whereas prandial insulin 1 $AUC_{0-2\text{ h}}$ increased to a greater extent in the glimepiride group ($33 \pm 18 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for vildagliptin vs. $91 \pm 19 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for glimepiride) ($P = 0.017$).

Glucagon, GLP-1, and insulin secretion

Prandial glucagon $AUC_{0-2\text{ h}}$ decreased from baseline with vildagliptin treatment but increased with glimepiride ($-3.4 \pm 1.6 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for vildagliptin vs. $3.8 \pm 1.7 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for glimepiride; $P < 0.001$; Fig. 1A). Prandial intact GLP-1 $AUC_{0-2\text{ h}}$ increased in both groups but was much larger after vildagliptin ($18.8 \pm 1.8 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for vildagliptin vs. $1.6 \pm 1.7 \text{ pmol} \cdot \text{h}^{-1} \cdot \text{l}^{-1}$ for glimepiride; Fig. 1B). Insulin secretion rate relative to glucose (0–2 h) increased in both groups ($4.3 \pm 0.9 \text{ pmol}/\text{min}/\text{m}^2/\text{mmol/l}$ for glimepiride vs. $1.6 \pm 0.9 \text{ pmol}/\text{min}/\text{m}^2/\text{mmol/l}$ for vildagliptin; $P = 0.022$; Fig. 1C). Prandial insulin-to-glucagon ratio ($AUC_{0-2\text{ h}}$ for insulin/ $AUC_{0-2\text{ h}}$ for glucagon) changed by -1.1 ± 9.3 (baseline 7.4 ± 0.4) pmol insulin/ pmol glucagon in the vildagliptin group versus -7.3 ± 9.8 (baseline 7.1 ± 0.4) pmol insulin/ pmol glucagon in the glimepiride group ($P = 0.62$).

Insulin resistance

Fasting insulin ($15.2 \pm 1.6 \text{ pmol/l}$ for glimepiride vs. $5.7 \pm 1.6 \text{ pmol/l}$ for vildagliptin; $P < 0.001$) and HOMA-IR (0.11 ± 0.10 for vildagliptin vs. 0.63 ± 0.10 for glimepiride; $P < 0.001$; Fig. 1D) increased in both treatment groups with larger increases with glimepiride.

CONCLUSIONS— Vildagliptin reduces glucagon levels after a standard mixed meal in patients with type 2 diabetes who are treated with metformin, as




Figure 1—Changes in prandial glucagon $AUC_{0-2\text{ h}}$, prandial GLP-1 $AUC_{0-2\text{ h}}$, insulin secretory rate relative to glucose (ISR/G), and HOMA-IR after up to a 2-year (mean 1.8 years) add-on treatment with vildagliptin (50 mg b.i.d.; $n = 137$) or glimepiride (up to 6 mg; $n = 121$) in patients with type 2 diabetes inadequately controlled with prior metformin therapy. Means \pm SD are shown. The asterisk indicates $P < 0.001$ (A), $P < 0.001$ (B), $P = 0.022$ (C), and $P < 0.001$ (D) between the groups.

was previously demonstrated in individuals with IGT (6), IFG (7), and type 1 diabetes (8). This effect appears to be the result of a GLP-1–induced improvement in glucose sensitivity of the α -cells (3,9). In contrast, glimepiride increases glucagon levels, which may be the result of attenuation of the glucose sensitivity of the α -cells with uncoupling of glucose dependency (10).

With respect to β -cell function, vildagliptin increases glucose sensitivity (11), whereas indirect data suggest that sulfonylurea uncouples the glucose dependency of the β -cells, which attenuates glucose sensitivity (10). In this study, this resulted in increased insulin secretion by both treatments, although vildagliptin did not increase the insulin secretion rate as much as glimepiride. The greater insulin secretion rate in the glimepiride group was balanced by less insulin resistance in the vildagliptin

group, as reflected by HOMA-IR and lower postprandial glucagon levels resulting in similar glucose levels.

In summary, prandial glucagon is increased by glimepiride but reduced by vildagliptin. Hence, vildagliptin effectively targets glucagon secretion in the treatment of diabetes. This together with the lesser increase in insulin by vildagliptin than by glimepiride may provide a pathophysiological explanation for the observation that vildagliptin's effect of reducing A1C levels below 7% is associated with much less hypoglycemia than glimepiride while being associated with the same A1C reduction (4).

Acknowledgments— This study was funded by Novartis Pharmaceuticals. D.R.M. is a Senior Investigator of the National Institute of Health Research (NIHR), U.K., and acknowledges NIHR funding support. E.F. has

received consulting fees from Novartis Pharmaceuticals. V.A.F. has received funding for research and consulting/speaking for Novartis as well as from other manufacturers of drugs in this class, including Merck, Novo-Nordisk, Eli Lilly, Takeda, and Glaxo. B.Z. has received research support and consulting fees from Novartis Pharmaceuticals. B.A. has received funding and consulting fees from Novartis Pharmaceuticals. D.R.M. has received consulting fees from Novartis as well as from other manufacturers of drugs in this class, including Novo-Nordisk and Merck. He has also received lecturing honoraria from Eli Lilly and Novo-Nordisk. J.F. and S. D. are employees of Novartis Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

The authors gratefully acknowledge the investigators, those who participated in any part of the study (listed previously in Ferrannini et al. [4]), staff at the 402 participating sites, and the editorial assistance of Gali Venkateswara Prasad and Shivali Arora, PhD (both from Novartis, India).

References

1. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. *J Clin Endocrinol Metab* 2007;92:1249–1255
2. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. *J Clin Endocrinol Metab* 2004;89:2078–2084
3. Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. *Int J Clin Pract Suppl* 2008;159:8–14
4. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2009;11:157–166
5. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. *Diabetes Obes Metab* 2008;10:931–938
6. Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. *Diabetes Care* 2008;31:30–35
7. Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β -cell function and insulin sensitivity in subjects with impaired fasting glucose. *Diabetes* 2008;31:108–113
8. Foley JE, Ligueros-Saylan M, He YL, Holst JJ, Deacon CF, Dunning BE, Leone-Jones A, Yu T, Kelley DE. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. *Horm Metab Res* 2008;40:727–730
9. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2009;94:1236–1243
10. de Heer J, Holst JJ. Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. *Diabetes* 2007;56:438–443
11. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE. Characterization of the influence of vildagliptin on model-assessed β -cell function in patients with type 2 diabetes and mild hyperglycemia. *J Clin Endocrinol Metab* 2008;93:103–109